Back to Journals » Patient Intelligence » Volume 2 » Default

Application of PIP data in health economic models for market access

Authors van Dongen N, Nuijten MJ

Published 24 November 2010 Volume 2010:2(Default) Pages 53—58


Review by Single-blind

Peer reviewer comments 2

Nadine van Dongen1, Mark JC Nuijten2
1Van Dongen Research Ltd, London, UK; 2Ars Accessus Medica, Amsterdam, The Netherlands

Abstract: Cost-effectiveness data from a state of the art health economic analysis should permit reliable, reproducible, and verifiable insights into the effectiveness of a drug and the possible savings that might be achieved relative to other drugs and/or treatments. The data for a model may come from a variety of sources and are subject to varying degrees of uncertainty. The reliability of the estimates depends on the choice of the data sources. Data sources for the variables being used in a model may be clinical trials, databases, medical records, and Delphi panels. A limitation of these data sources is that they often lack the input from the patient’s perspective. Patient Intelligence applications can provide data to be used in health economic models for any given situation regarding treatment of persons suffering from a disorder, disease, or complaint. The objective of this paper to explore the opportunity of integrating patient data generated by Patient Intelligence applications as an alternative data source for a Delphi panel and databases in health economic models.

Keywords: effectiveness, Patient Intelligence, data source, Delphi panel

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other articles by this author:

Readers of this article also read:

Aloe vera gel facilitates re-epithelialization of corneal alkali burn in normal and diabetic rats

Atiba A, Wasfy T, Abdo W, Ghoneim A, Kamal T, Shukry M

Clinical Ophthalmology 2015, 9:2019-2026

Published Date: 28 October 2015

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Educating future leaders in patient safety

Leotsakos A, Ardolino A, Cheung R, Zheng H, Barraclough B, Walton M

Journal of Multidisciplinary Healthcare 2014, 7:381-388

Published Date: 19 September 2014

Topical diclofenac in the treatment of osteoarthritis of the knee

Niklas Schuelert, Fiona A Russell, Jason J McDougall

Orthopedic Research and Reviews 2011, 3:1-8

Published Date: 6 February 2011

Azithromycin in DuraSite® for the treatment of blepharitis

Jodi Luchs

Clinical Ophthalmology 2010, 4:681-688

Published Date: 28 June 2010

Tapentadol immediate release: a new treatment option for acute pain management

Marc Afilalo, Jens-Ulrich Stegmann, David Upmalis

Journal of Pain Research 2010, 3:1-9

Published Date: 8 February 2010